Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

ClinicalTrials.gov ID: NCT00355082

Public ClinicalTrials.gov record NCT00355082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.

Study identification

NCT ID
NCT00355082
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
226 participants

Conditions and interventions

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2006 (Type not available)
Primary completion
Nov 2008 (Actual)
Completion
Nov 2008 (Actual)
Last update posted
Jan 2, 2017

2006 – 2008

United States locations

U.S. sites
67
U.S. states
31
U.S. cities
59
Facility City State ZIP Site status
GSK Investigational Site Alabaster Alabama 35007 —
GSK Investigational Site Litchfield Park Arizona 85340 —
GSK Investigational Site Mesa Arizona 85201 —
GSK Investigational Site Phoenix Arizona 85003 —
GSK Investigational Site Phoenix Arizona 85013 —
GSK Investigational Site Tucson Arizona 85724 —
GSK Investigational Site Tucson Arizona 85741 —
GSK Investigational Site Fayetteville Arkansas 72703 —
GSK Investigational Site Los Angeles California 90073 —
GSK Investigational Site Pasadena California 91105 —
GSK Investigational Site Santa Ana California 92705 —
GSK Investigational Site Santa Monica California 90404 —
GSK Investigational Site Danbury Connecticut 06810 —
GSK Investigational Site Fairfield Connecticut 06824 —
GSK Investigational Site Newark Delaware 19713 —
GSK Investigational Site Jacksonville Florida 32224 —
GSK Investigational Site Loxahatchee Groves Florida 33470 —
GSK Investigational Site Sunrise Florida 33351 —
GSK Investigational Site Tampa Florida 33613 —
GSK Investigational Site Atlanta Georgia 30338 —
GSK Investigational Site Atlanta Georgia 30342 —
GSK Investigational Site Decatur Georgia 30033 —
GSK Investigational Site Boise Idaho 83702 —
GSK Investigational Site Chicago Illinois 60611 —
GSK Investigational Site Chicago Illinois 60637 —
GSK Investigational Site Flossmoor Illinois 60422 —
GSK Investigational Site Urbana Illinois 61801 —
GSK Investigational Site Des Moines Iowa 50309 —
GSK Investigational Site Lexington Kentucky 40513 —
GSK Investigational Site Lexington Kentucky 40536 —
GSK Investigational Site Louisville Kentucky 40202 —
GSK Investigational Site New Orleans Louisiana 70115 —
GSK Investigational Site Bethesda Maryland 20817 —
GSK Investigational Site Glen Burnie Maryland 21061 —
GSK Investigational Site Pikesville Maryland 21208 —
GSK Investigational Site Springfield Massachusetts 01104 —
GSK Investigational Site Detroit Michigan 48202 —
GSK Investigational Site Minneapolis Minnesota 55455 —
GSK Investigational Site Saint Cloud Minnesota 56303 —
GSK Investigational Site Hattiesburg Mississippi 39401 —
GSK Investigational Site Kansas City Missouri 64111 —
GSK Investigational Site St Louis Missouri 63104 —
GSK Investigational Site St Louis Missouri 63110 —
GSK Investigational Site Henderson Nevada 89014 —
GSK Investigational Site Las Vegas Nevada 81902 —
GSK Investigational Site Las Vegas Nevada 89106 —
GSK Investigational Site Edison New Jersey 08818 —
GSK Investigational Site Vorhees New Jersey 08043 —
GSK Investigational Site Lawrence New York 11559 —
GSK Investigational Site Plainview New York 11803 —
GSK Investigational Site Syracuse New York 13210 —
GSK Investigational Site Asheville North Carolina 28803 —
GSK Investigational Site Columbus Ohio 43210-1296 —
GSK Investigational Site Oklahoma City Oklahoma 73112 —
GSK Investigational Site Philadelphia Pennsylvania 19107 —
GSK Investigational Site Sellersville Pennsylvania 18960 —
GSK Investigational Site Dallas Texas 75230 —
GSK Investigational Site Houston Texas 77025 —
GSK Investigational Site San Antonio Texas 78229 —
GSK Investigational Site San Antonio Texas 78258 —
GSK Investigational Site Temple Texas 76502 —
GSK Investigational Site Midvale Utah 84047 —
GSK Investigational Site Renton Washington 98055 —
GSK Investigational Site Charleston West Virginia 25301 —
GSK Investigational Site Morgantown West Virginia 26506 —
GSK Investigational Site Madison Wisconsin 53715 —
GSK Investigational Site Milwaukee Wisconsin 53215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00355082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 2, 2017 · Synced Oct 31, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00355082 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →